Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval (March 2)

(Corrects first bullet in the March 2 news item to say FDA decision is expected in early second quarter, ​not April)

March 2 (Reuters) – Eli Lilly CFO ‌Lucas Montarce said on Monday it is preparing to launch its new oral obesity drug, orforglipron, in the United States as early as the second ‌quarter ​of this year, once ⁠it gets approval from ⁠the Food and Drug Administration.

“On track in the US, expect to see potentially that product coming into the market as early ​as Q2,” Montarce said at the TD Cowen healthcare conference.

(Reporting by Kamal Choudhury in Bengaluru; Editing by ​Shinjini Ganguli)